CDK1 and cancer: The analysis revealed that these proteins represented not only currently approved drug targets but also investigational targets, still undergoing research on their potential therapeutic utility and effectiveness in the context of combination therapies that present interest for targeting alternative biological pathways at lower effective dosages (e.g., AURKA, AURKB, CDK1, CDK2, TOP2A) and for counteracting the proliferation of drug resistant cancer cells.